Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Cxlusa13 enrolled

Overview

This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Infectious Keratitis

Interventions

Ultraviolet-A and riboflavinOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects must be 18 years of age or older. 2. Ability to provide written informed consent. 3. Likely to complete all study visits. 4. Subjects must have one eye that with a diagnosis of infectious keratitis. Exclusion Criteria: 1. A corneal perforation. 2. Descemetocele. 3. Pregnancy or breastfeeding. 4. Active Herpes corneal disease. 5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.

Locations (6)

Schwartz Laser Eye Center

Scottsdale, Arizona, United States

Davidorf Eye Group

West Hills, California, United States

Corneal Consultants of Colorado, PC

Littleton, Colorado, United States

Center for Excellence in Eye Care

Miami, Florida, United States

Outcomes

Primary Outcomes

Resolution of Signs and Symptoms of Infectious Keratitis

Time frame: Subjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.